CaboCombo: a prospective, phase IV study of first-line cabozantinib  + nivolumab for advanced renal cell carcinoma

Future Oncology, Ahead of Print.

Source: Future Oncology - July 5, 2023 Category: Cancer & Oncology Authors: Philippe Barth élémy Pascale Dutailly Bryan Qvick Valerie Perrot Elena Verzoni Source Type: research